The forthcoming European approval of Hospira Inc./Celltrion Inc.’s biosimilar infliximab – a copy of rheumatoid arthritis drug Remicade – is an important date on the biosimilars calendar. Assuming, as most do, that the European Medicines Agency (EMA) will give it the nod, the drug – which Celltrion will co-market in the EU 27 as Remsima and Hospira will sell as Inflectra – will be the first biosimilar mAb to reach Europe, or any Western developed market. The first of a wave of complex biosimilars, mostly monoclonal antibodies, it could generate far more exciting returns than seen for first-generation copycat biologics such as erythropoietin (EPO) or filgrastim.
The case in favor of biosimilars looks even more compelling in the midst of the deepest and longest economic recession...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?